Definium Therapeutics Inc.
(NASDAQ:DFTX) shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder—with the trial meeting its primary and all key secondary efficacy endpoints.
Definium stock is challenging resistance.
Why is DFTX stock breaking out?
The Results The Emerge study evaluated a single dose of DT120 ODT 100 µg—a lysergide-based treatment—in a randomized, double-blind, placebo-controlled Phase 3 trial.
